Advanced search
Publication Cover
Future Virology Volume 2, 2007 - Issue 6
Submit an article Journal homepage
70
Views
0
CrossRef citations to date
0
Altmetric
Review

Lentiviruses in Cancer Immunotherapy

Karine BreckpotMedical School of the Vrije Universiteit Brussel,Laboratory of Molecular & Cellular Therapy,Department of Physiology-Immunology,Laarbeeklaan 103 Building E,B-1090,Brussels,Belgium. Tel.: +32 2477 4569; Fax: +32 2477 4568; [email protected]
&
K ThielemansCorrespondence[email protected]
Pages 597-606 | Published online: 31 Oct 2007

Bibliography

  • Ehrlich P : Ueber den jetzigen Stand der Karzinomforschung.Ned. Tijdschr. Geneesk.5, 273–290 (1909).
  • Burnet FM : The concept of immunological surveillance.Prog. Exp. Tumor Res.13, 1–27 (1970).
  • Boon T , van der BruggenP: Human tumor antigens recognized by T lymphocytes. J. Exp. Med.183(3), 725–729 (1996).
  • Van den Eynde BJ , van der BruggenP: T cell defined tumor antigens. Curr. Opin. Immunol.9(5), 684–693 (1997).
  • Breckpot K , HeirmanC, NeynsB, ThielemansK: Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.J. Gene Med.6(11), 1175–1188 (2004).
  • Schroers R , SinhaI, SegallHet al.: Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system.Mol. Ther.1(2), 171–179 (2000).
  • Dyall J , LatoucheJB, SchnellS, SadelainM: Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes.Blood97(1), 114–121 (2001).
  • Firat H , ZennouV, Garcia-PonsFet al.: Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy.J. Gene Med.4(1), 38–45 (2002).
  • Breckpot K , DullaersM, BonehillAet al.: Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.J. Gene Med.5(8), 654–667 (2003).
  • Lizee G , GonzalesMI, TopalianSL: Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.Hum. Gene Ther.15(4), 393–404 (2004).
  • Lurquin C , LetheB, De PlaenEet al.: Contrasting frequencies of antitumor and antivaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp. Med.201(2), 249–257 (2005).
  • Yang Y , HuangCT, HuangX, PardollDM: Persistent Toll-like receptor signals are required for reversal of regulatory T-cell-mediated CD8 tolerance.Nat. Immunol.5(5), 508–515 (2004).
  • Fehervari Z , SakaguchiS: CD4+ Tregs and immune control.J. Clin. Invest.114(9), 1209–1217 (2004).
  • Gautier G , HumbertM, DeauvieauFet al.: A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.J. Exp. Med.201(9), 1435–1446 (2005).
  • Warger T , OsterlohP, RechtsteinerGet al.: Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo.Blood108(2), 544 (2006).
  • Pichlmair A , DieboldSS, GschmeissnerSet al.: Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J. Virol.81(2), 539–547 (2007).
  • Brown BD , SitiaG, AnnoniAet al.: In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.Blood109(7), 2797–2805 (2006).
  • Beignon AS , McKennaK, SkoberneMet al.: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest.115(11), 3265–3275 (2005).
  • Tan PH , BeutelspacherSC, XueSAet al.: Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.Blood105(10), 3824–3832 (2005).
  • Breckpot K , EmeagiP, DullaersM, MichielsA, HeirmanC, ThielemansK: Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther.18(6), 536–546 (2007).
  • Delenda C : Lentiviral vectors: optimization of packaging, transduction and gene expression.J. Gene Med.6 Suppl 1, S125–138 (2004).
  • Watson DJ , KobingerGP, PassiniMA, WilsonJM, WolfeJH: Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.Mol. Ther.5(5 Pt 1), 528–537 (2002).
  • Wong LF , AzzouzM, WalmsleyLEet al.: Transduction patterns of pseudotyped lentiviral vectors in the nervous system.Mol. Ther.9(1), 101–111 (2004).
  • Cui Y , GolobJ, KelleherE, YeZ, PardollD, ChengL: Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells.Blood99(2), 399–408 (2002).
  • Cronin J , ZhangXY, ReiserJ: Altering the tropism of lentiviral vectors through pseudotyping.Curr. Gene Ther.5(4), 387–398 (2005).
  • Segura MM , KamenA, GarnierA: Downstream processing of oncoretroviral and lentiviral gene therapy vectors.Biotechnol. Adv.24(3), 321–337 (2006).
  • Sinn PL , HickeyMA, StaberPDet al.: Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha.J. Virol.77(10), 5902–5910 (2003).
  • Sinn PL , SauterSL, McCrayPBJr: Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production. Gene Ther.12(14), 1089–1098 (2005).
  • Breckpot K , AertsJL, ThielemansK: Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.Gene Ther.14(11), 847–862 (2007).
  • Burke B : Macrophages as novel cellular vehicles for gene therapy.Expert Opin. Biol. Ther.3(6), 919–924 (2003).
  • von Bergwelt-Baildon M , Shimabukuro-VornhagenA, PopovAet al.: CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.Blood107(7), 2786–2789 (2006).
  • Van den Bosch GA , PonsaertsP, NijsGet al.: Ex vivo induction of viral antigen-specific CD8 T-cell responses using mRNA-electroporated CD40-activated B cells. Clin. Exp. Immunol.139(3), 458–467 (2005).
  • Hellebrand E , MautnerJ, ReisbachGet al.: Epstein–Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination.Gene Ther.13(2), 150–162 (2006).
  • Fujiwara H , MelenhorstJJ, El OuriaghliFet al.: In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B-cells gene modified to express primary granule proteins. Clin. Cancer Res.11(12), 4495–4503 (2005).
  • Tuyaerts S , AertsJL, CorthalsJet al.: Current approaches in dendritic cell generation and future implications for cancer immunotherapy.Cancer Immunol. Immunother.56(10), 1513–1537 (2007).
  • Ribas A : Genetically modified dendritic cells for cancer immunotherapy.Curr. Gene Ther.5(6), 619–628 (2005).
  • Banchereau J , BriereF, CauxCet al.: Immunobiology of dendritic cells.Annu. Rev. Immunol.18, 767–811 (2000).
  • Unutmaz D , KewalRamaniVN, MarmonS, LittmanDR: Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.J. Exp. Med.189(11), 1735–1746 (1999).
  • Breckpot K , CorthalsJ, HeirmanCet al.: Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells.Hum. Gene Ther.15(6), 562–573 (2004).
  • Oki M , AndoK, HagiharaMet al.: Efficient lentiviral transduction of human cord blood CD34+ cells followed by their expansion and differentiation into dendritic cells.Exp. Hematol.29(10), 1210–1217 (2001).
  • Salmon P , KindlerV, DucreyO, ChapuisB, ZublerRH, TronoD: High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.Blood96(10), 3392–3398 (2000).
  • Metharom P , EllemKA, SchmidtC, WeiMQ: Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum. Gene Ther.12(18), 2203–2213 (2001).
  • Esslinger C , ChapatteL, FinkeDet al.: In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses.J. Clin. Invest.111(11), 1673–1681 (2003).
  • Zarei S , LeubaF, ArrighiJF, HauserC, PiguetV: Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation.J. Allergy Clin. Immunol.109(6), 988–994 (2002).
  • Breckpot K , HeirmanC, De GreefC, van der BruggenP , ThielemansK: Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J. Immunol.172(4), 2232–2237 (2004).
  • Dullaers M , Van MeirvenneS, HeirmanCet al.: Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther.13(7), 630–640 (2006).
  • Wang B , HeJ, LiuC, ChangLJ: An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.Vaccine,24(17), 3477–3489 (2006).
  • Metharom P , EllemKA, WeiMQ: Gene transfer to dendritic cells induced a protective immunity against melanoma.Cell. Mol. Immunol.2(4), 281–288 (2005).
  • He Y , ZhangJ, MiZ, RobbinsP, Falo LDJr: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T-cell responses and therapeutic immunity. J. Immunol.174(6), 3808–3817 (2005).
  • VandenDriessche T , ThorrezL, NaldiniLet al.: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo.Blood100(3), 813–822 (2002).
  • Palmowski MJ , LopesL, IkedaY, SalioM, CerundoloV, CollinsMK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.J. Immunol.172(3), 1582–1587 (2004).
  • He Y , ZhangJ, DonahueC, FaloLDJr: Skin-derived dendritic cells induce potent CD8+ T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity24(5), 643–656 (2006).
  • Kim JH , MajumderN, LinH, WatkinsS, FaloLDJr, YouZ: Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum. Gene Ther.16(11), 1255–1266 (2005).
  • Chapatte L , ColombettiS, CerottiniJC, LevyF: Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.Cancer Res.66(2), 1155–1160 (2006).
  • Gruber A , Kan-MitchellJ, KuhenKL, MukaiT, Wong-StaalF: Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro.Blood96(4), 1327–1333 (2000).
  • Chen X , HeJ, ChangLJ: Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells.Retrovirology1, 37 (2004).
  • Granelli-Piperno A , GolebiowskaA, TrumpfhellerC, SiegalFP, SteinmanRM: HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T-cell regulation.Proc. Natl Acad. Sci. USA101(20), 7669–7674 (2004).
  • Vandendriessche T , ThorrezL, Acosta-SanchezAet al.: Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.J. Thromb. Haemost.5(1), 16–24 (2007).
  • Higashikawa F , ChangL: Kinetic analyses of stability of simple and complex retroviral vectors.Virology280(1), 124–131 (2001).
  • Azzouz M , KingsmanSM, MazarakisND: Lentiviral vectors for treating and modeling human CNS disorders.J. Gene Med.6(9), 951–962 (2004).
  • Mitta B , RimannM, FusseneggerM: Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles.Metab. Eng.7(5–6), 426–436 (2005).
  • DePolo NJ , ReedJD, SheridanPLet al.: VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.Mol. Ther.2(3), 218–222 (2000).
  • Croyle MA , CallahanSM, AuricchioAet al.: PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol.78(2), 912–921 (2004).
  • Chazal N , SingerG, AikenC, HammarskjoldML, RekoshD: Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J. Virol.75(8), 4014–4018 (2001).
  • Schlehuber LD , RoseJK: Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein.J. Virol.78(10), 5079–5087 (2004).
  • Dreja H , PiechaczykM: The effects of N-terminal insertion into VSV-G of an scFv peptide.Virol. J.3, 69 (2006).
  • Peng KW , PhamL, YeHet al.: Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors.Gene Ther.8(19), 1456–1463 (2001).
  • Kang Y , SteinCS, HethJAet al.: In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.J. Virol.76(18), 9378–9388 (2002).
  • Noti JD , ReinemannBC, PetrusMN: Sp1 binds two sites in the CD11c promoter in vivo specifically in myeloid cells and cooperates with AP1 to activate transcription.Mol. Cell. Biol.16(6), 2940–2950 (1996).
  • Dzionek A , SohmaY, NagafuneJet al.: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction.J. Exp. Med.194(12), 1823–1834 (2001).
  • Takahara K , OmatsuY, YashimaYet al.: Identification and expression of mouse Langerin (CD207) in dendritic cells.Int. Immunol.14(5), 433–444 (2002).
  • Chandrashekran A , GordonMY, CasimirC: Targeted retroviral transduction of c-kit+ hematopoietic cells using novel ligand display technology.Blood104(9), 2697–2703 (2004).
  • Yang L , BaileyL, BaltimoreD, WangP: Targeting lentiviral vectors to specific cell types in vivo.Proc. Natl Acad. Sci. USA103(31), 11479–11484 (2006).
  • Schulz O , DieboldSS, ChenMet al.: Toll-like receptor 3 promotes cross-priming to virus-infected cells.Nature433(7028), 887–892 (2005).
  • Rowe HM , LopesL, IkedaYet al.: Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.Mol. Ther.13, 310–319 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.